Risk factor
Significant default risk
Profitability factor
Favourable analyst view
About
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of AVBP is 40 and suggests 62% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell